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A B S T R A C T
A deep eutectic solvent (DES) is a mixture of two or more chemicals that interact via hydrogen bonding and has a
melting point far below that of the individual components. DESs have been proposed as alternative solvents for
poorly soluble active pharmaceutical ingredients (API). In this study, the solvation capacities of six deep eutectic
solvents were compared to water and three conventional pharmaceutical solvents (PEG 300, ethanol and gly-
cerol) for 11 APIs. The experimentally determined solubilities were compared to computational solubilities
predicted by the Conductor-like Screening Model for Real Solvents (COSMO-RS). While the conventional
pharmaceutical solvents PEG 300 and ethanol were the best solvents for the majority of the studied APIs, API-
DES combinations were identified, which exceeded the API solubility found in the conventional pharmaceutical
solvents. Furthermore, it was also possible to obtain high solubilities in the DESs relative to water, suggesting
DESs to be potential solvents for poorly water soluble APIs. In addition, the relative increase in solubility found
in the experimental data could be well predicted ab initio using COSMO-RS. Hence, COSMO-RS may in the future
be used to reduce the experimental screening of potential DESs for a given API.
1. Introduction
In 2003, a new type of solvent called deep eutectic solvent (DES)
with good solvation properties was described by (Abbott et al., 2003).
DESs are mixtures of two or more chemicals with a melting point below
the melting point of the individual components. DESs are formed by
mixing a hydrogen bond acceptor (HBA), typically a quaternary am-
monium salt, and a hydrogen bond donor (HBD) (Smith et al., 2014).
The first reported DES was a 1:2 molar mixture of choline chloride and
urea. Despite melting points of 133 °C and 302 °C for urea and choline
chloride, respectively, the mixture was liquid at room temperature with
a freezing point of 12 °C (Abbott et al., 2003). After the discovery of the
first DES, many combinations of HBA and HBDs such as sugars, polyols,
carboxylic acids, and amino acids have been reported to form DESs (Dai
et al., 2013; Smith et al., 2014).
The diversity of the starting materials and numbers of combinations
allowed the design of numerous DESs with specific physical properties
and the ability to dissolve solutes of different nature. The starting
materials of DESs are often abundantly found in nature and tox-
icologically well characterised as non-toxic. DESs have therefore gen-
erally been considered non-toxic, biocompatible, and biodegradable.
However, a few studies of DES toxicity and biodegradability have re-
ported examples of synergetic toxicologically effects between the in-
dividual components when presented as a DES system (Hayyan et al.,
2013a; Hayyan et al., 2013b).
As a promising alternative to toxic and environmentally harmful
organic solvents, DES have been found applications in the fields of
electrodeposition (Abbott et al., 2007; Abbott et al., 2009), biocatalysis
(Durand et al., 2013; Zhao et al., 2011; Zhao et al., 2013), extraction of
biomaterials, and as medium for chemical synthesis (Gouveia et al.,
2016; Handy and Lavender, 2013). A few published studies have sug-
gested DESs as promising solvents for active pharmaceutical ingredients
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(APIs) with poor aqueous solubility and as an alternative to the con-
ventional pharmaceutical solvents (Li and Lee, 2016; Lu et al., 2016;
Morrison et al., 2009). High solubilities of nonsteroidal anti-in-
flammatory APIs have been reported in DES systems for which the
highest solubility (383.4mg/mL) was measured for ibuprofen in a DES
system containing tetrapropylammonium bromide and 1,2-propanediol
in a 1:2 molar ratio (Lu et al., 2016). The solubility of the poorly soluble
API itraconazole have been reported to be 22mg/mL in a DES made of
choline chloride-malonic acid at a 1:1 molar ratio and 53.6mg/mL in a
DES made of choline chloride-glycolic acid-oxalic acid at a 1:1.6:0.4
molar ratio. These solubilities are 22,000 and 53,600 fold higher than
the solubility in water, respectively (Li and Lee, 2016; Morrison et al.,
2009). However, none of these studies investigated the solubility of a
given API in other conventional pharmaceutical solvents making a true
evaluation of the solvation capabilities of DESs difficult. As a result of
the vast possibility to combining HBAs with HBDs, the number of po-
tential DESs has been hypothesised to be around 106 (Francisco et al.,
2013). The high number of potential DESs request computational
methods that can reduce experimental work associated with solubility
screening for promising DES-API combinations.
Various computational methods have been developed to predict the
solubility of small organic molecules (Bergström and Larsson, 2018).
The solubility of an API is determined by the solutes' association with
the solvent and its own crystal lattice. Hence, the aqueous solubility of
an API can be estimated by the modified general solubility equation
from the octanol-water partitioning coefficient (logP) and melting point
of the solute (Jain and Yalkowsky, 2001). Although this method is
simple and based on thermodynamics, it is limited to the aqueous so-
lubility and therefore, not applicable for DESs. The relative solubility
(solubility in solvent1/solubility in solvent2) can be predicted from first
principles methods that do not rely on empirical data. These methods
do not account for the fusion energy of the solid state but only on the
molecular interactions in the liquid phase. The first of its kind was the
solubility parameter developed by Hildebrand and Scott (Hildebrand
and Scott, 1950), which was later divided into three partial solubility
parameters by Hansen (Hansen, 2002). The Hansen solubility para-
meter is the squared value of partial solubility parameters that de-
scribes the contribution of the polar-, dispersion- and hydrogen-
bonding-interactions to the solubility (Hansen, 2002). The solubility
parameter can be experimentally determined by intrinsic viscosity
measurements (Han et al., 2013) or chromatography (Huang, 2004)
and estimated by a group contribution method (Van Krevelen and Te
Nijenhuis, 2009). If the difference of Hansen Solubility Parameter of
solute and the solvent are< 0.5 they are estimated to be miscible.
However, the difference in Hansen Solubility Parameter cannot be di-
rectly translated into an absolute solubility. Another method is the
Flory-Huggins solution theory, which is a mathematical model to esti-
mate the miscibility between a solvent and solute by investigating an
interaction parameter that represents the free energy of mixing (Flory,
1953). The interaction parameter can be experimentally determined by
thermal analysis of mixtures (Rask et al., 2018) or derived from the
Hansen Solubility Parameter (Lindvig et al., 2002). Other first principle
methods include the purely computational methods molecular dy-
namics (MD) and Monte Carlo (MC) based simulations as well as the
conductor like screening model (COSMO) and COSMO-RS (RS for rea-
listic solvation). MD and MC simulations are explicit models, which can
provide valuable insights into molecular solute-solvent interactions
(Bergström and Larsson, 2018). These two methods are limited by their
high computational costs due to extensive sampling and high degree of
freedom for solvent and solute molecules. On the other hand, COSMO
and COSMO-RS are much faster computational methods but do not give
any explicit information on a molecular level (Klamt, 2005).
The absolute solubility has been computationally predicted by
quantitative structural property relationship (QSPR) by modelling
molecular descriptors with multi linear regression (Katritzky et al.,
1998; Votano et al., 2004), artificial neural network (Huuskonen et al.,
1997; Votano et al., 2004), partial least square (Votano et al., 2004),
and by deep learning (Lusci et al., 2013) among other modelling ap-
proaches. These approaches require experimental data input in order to
establish a QSPR that can be used to computationally predict molecules
with an unknown solubility. QSPR methods are limited by the chemical
space of the training set, and predictions of solute or solvent groups not
covered by the training set can be difficult to accurately predict abso-
lute solubilities. However, the advantage of QSPR methods is that they
are computational inexpensive and suitable for high throughput
screening in early drug development.
Computational methods to determine the crystal structure and en-
ergy are fewer and remain a greater scientific challenge. It has been
possible to predict the fusion temperature by a QSPR method with a
RMSE of 35.1 °C (Bergström et al., 2003). The sixth blind test of organic
crystal structure prediction methods revealed that the current compu-
tational crystal structure prediction methods have improved re-
markably, however, none of the 21 submitted methods was consistently
able to predict all the experimental structures (Reilly et al., 2016).
Given the lack of QSPR methods for DESs to the best of the authors'
knowledge COSMO-RS was deemed to be the best suited computational
method for solubility screening of APIs in DESs.
The aim of this study was to first compare the solubility of 11 APIs
in six different DESs to their solubility in water and three commonly
used conventional pharmaceutical solvents in formulations; and second
to evaluate the ability of COSMO-RS as an ab initio predictive screening
tool to rank the solvation capabilities of the different solvents.
2. Theory of the computational approach
Computational prediction of solvent rank order is useful in order to
reduce labour-intensive experimental work and sample consumption
during early API development where only limited amount of material is
available. Currently, the Conductor-like Screening Model for Real
Solvents (COSMO-RS) is considered one of the most accurate ab initio
computational methods available for rank ordering of solvents.
COSMO-RS is a combination of a conductor-like screening model
(COSMO) and statistical thermodynamic treatment of interacting sur-
faces. Hence, COSMO-RS represent the solvent and solute as small
conductor-segments and correct the chemical potential for segment
interactions. In the following, the basic concept of COSMO-RS will be
described briefly. For a detailed theoretical background of COSMO-RS
and COSMO the reader is referred (Eckert and Klamt, 2002) or to a
textbook written by (Klamt, 2005).
COSMO-RS considers dispersive, misfit and hydrogen bond (HB)
interactions between solute and solvent molecules for calculation of the
chemical potential and thus, can be used to estimate the solubility of a
solute in a solvent but also other thermodynamic properties.
COSMO treats the solvent as a continuum with an infinite permit-
tivity (conductor), which enables calculation of the interaction energy
between solvent and solute from the surface charge density (σ) of the
solute. Hence, a conductor represents the solvent. However, this model
is unable to resemble the polar solvents reorientation of permanent
dipole moments due to electrostatic interactions with solute molecules.
On the other hand, because of the homogenous distribution of the di-
pole moments of non-polar solvents, the conductor represents the sol-
vent reasonably well to obtain acceptable solvation predictions.
COSMO is selected as the starting point for COSMO-RS, i.e. the state of a
solute in a perfectly conducting medium (reference state) despite its
limitations. Hence, the σ-surface of the solute molecules is perfectly
screened. The first step in the COSMO-RS prediction is performing the
COSMO calculations through a quantum mechanical geometry optimi-
sation in a perfectly conducting medium of all the molecules of interest
(both solvents and solutes). The output COSMO-files describing the σ-
surface of these molecules. Although being time-consuming, the cal-
culations for each molecule can be saved for later use and thus only
need to be performed once. The second step is to divide the σ-surface
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into smaller molecular segments, where the VdW-, the misfit-, and HB-
interaction energies are calculated from pair wise interaction between
molecular surface segments (Fig. 1.B) with a corresponding σ-value.
The interaction energies are calculated as the energy difference from
reference state.
The conductor is assumed to behave as an average van der Waal
(VdW)-interaction-partner. Furthermore, it is assumed that in liquid
systems, molecular segments will have a VdW-interaction-partner at
any time within the VdW-distance. The interaction energy does not
differ from the reference state and is consequently neglected in further
calculations of the interaction energies. The next interaction to consider
is the electrostatic misfit between two segments. If two interacting
segments have the same but opposite directed σ-value, they have a
perfect electrostatic fit and the corresponding energy difference from
the reference state will hence be zero. However, this is rarely the case;
local electrostatic misfit will occur in the liquid due to thermal fluc-
tuations, steric hindrance or non-availability of the right interaction-
partner. The energy (E) difference from the reference state is calculated
in Eq. (1) as the squared sum of the two interactive segment's σ and σ′
from the solvent and solute molecule, respectively.
∆ ≅ ′ = + ′E a e σ σ a c σ σ( , ) ( )misfit contact misfit contact misfit 2 (1)
where a is the surface area (nm2) of the interacting segments, e is the
energy coefficient (kJ/mol/nm2) and c is a fitting parameter. The last
important interaction is the electrostatic attraction between hydrogen
atoms bound to an electronegative atom (HB-donor) and an atom
bearing a lone pair of electrons (HB-acceptor). For the formation of a
HB, the polarity of the HB-acceptor and -donor must overcome a
threshold of± 0.0082 e/Å2. These relationships are described by Eq.
(2), where σHB2 is the required threshold for HB formation and the
energy change is given by multiplication of σ and σ′.
∆ ≅ ′ = ′ −E a e σ σ a c σσ σ( , ) min(0, )HB contact HB contact HB HB2 (2)
The total energy difference from the reference state, caused by
electrostatic interactions, is calculated in Eq. (3) as the sum of the misfit
and HB energies.
∆ ≅ ′ = ′ + ′E a e σ σ a e σ σ e σ σ( , ) ( ( , ) ( , ))int contact int contact misfit HB (3)
Calculation of the surface segments interactions would be extremely
complex if the three-dimensional structure of the molecules is retained.
However, if the surface is reduced to individual segments (Fig. 1.B)
without 3-dimensional geometry restrictions, the calculations of the
energy become manageable. Even though neglecting the 3-dimensional
structure of the molecule intuitively seems incorrect, it has been shown
that this mathematical approach to simplify the calculations can be
done without considerable loss of prediction accuracy. A similar ap-
proximation is also used in group contribution methods, which is an-
other commonly used approach for ab initio predictions (Van Krevelen
and Te Nijenhuis, 2009). The distribution of surface segments according
to σ is a σ-profile and is given by Eq. (4).
∑=p σ x P σ( ) ( )S
X
i
X
i
i
(4)
Fig. 1. Schematic overview of the computational prediction process by COSMO-RS. A) The screening charge density (σ) and three-dimensional structure of for water
, choline chloride , indomethacin , and lactic acid . B) A representation of the molecular segmentation of the
molecule. C) The σ-profile of the solvent and solute. D) From the σ-profile the σ-potential is determined, which is used to calculate the chemical potential of a
solution.
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where xi is the mole fraction of the individual molecular components Xi.
An example of an σ-profile is seen in Fig. 1.C where the number of
segments with an σ-value below −0.0082 e/Å2 indicates HB-donating
ability and σ-value above +0.0082 e/Å2 indicates HB-accepting ability.
The σ-profile can be used to calculate the σ-potential, μs(σ), which is a
characteristic function describing the affinity of the solvent to a surface
segment of polarity σ. Eq. (5) is solved iteratively usually starting with
μS(σ′)= 0.
∫= − ⎡⎣⎢ ′ ′ × ⎧⎨⎩
− ′ + ′ ⎫⎬⎭
⎤
⎦⎥
μ σ kT
a
ln dσ p σ exp
a e σ σ μ σ
kT
( ) ( )
( ( , ) ( )
S
eff
S
eff int S
(5)
where k is the Boltzmann's constant, T the temperature, and aeff is the
effective contact area. An example of a μs(σ) is presented in Fig. 1.D. By
using the μs(σ), it is possible to calculate the chemical potential of solute
(X) in solvent (S) by solving Eq. (6).
∫= +μ γ dσp σ μ σ( ) ( )SX Comb SX X S, (6)
where pX(σ) is the σ-profile of X. The combinational term (γComb, SX)
corrects for the shape and size effects of X and S. From the chemical
potential, it is then possible to calculate a wide range of physico-
chemical properties. The solubility can be calculated by Eq. (7).
= − − ∆x μ μ G
RT
ln( )
[ ]
S
X
S
X
fus
(7)
where ln(xs) is the logarithmic molar solubility, μXis the chemical po-
tential of the pure compounds, and ΔGfus is the free energy of fusion.
ΔGfus cannot be estimated by the COSMO-RS method and orthogonal
computational methods must be used if experimental data is not
available. COSMO-RS has also found application in prediction of vapour
pressure, partition coefficients, and activity coefficients. In the context
of DES, COSMO-RS have been applied for quantitative predictions of
phase behaviour and tie-lines for ternary mixtures containing DES in
separation of aromatic−aliphatic hydrocarbon mixtures by liquid-li-
quid extraction (Gouveia et al., 2016). Furthermore, COSMO-RS has
been used to predict solid-liquid equilibria of sugar based DES (Silva
et al., 2018) and rank-ordering of DESs based on the activity coefficient
of rutin in an infinite dilution of rutin and DES (Jelinski and Cysewski,
2018).
3. Materials and methods
3.1. Materials
The following APIs were purchased from the respective companies:
celecoxib (AKScientific, Inc., Union City, CA, USA), cinnarizine and
theophylline (Sigma-Aldrich, Steinheim, Germany), flufenamic acid
(VWR International, Copenhagen, Denmark), ibuprofen (Chr. Olesen &
Co. A/S, Copenhagen, Denmark), indomethacin, naproxen and para-
cetamol (Fagron Nordic A/S, Copenhagen, Denmark), lidocaine
(UNIKEM A/S, Copenhagen, Denmark), and probucol (Tokyo Chemical
Industry Co., Ltd., Portland, USA). Aprepitant was kindly donated by
Merck (Kenilworth, NJ). Starting materials for the DESs were D-glucose
monohydrate (glucoseco), choline chloride, urea, glycerol, betaine, all
purchased from Sigma-Aldrich (Steinheim, Germany). DL-Lactic acid
was purchased from VWR International (Copenhagen, Denmark). The
conventional pharmaceutical solvents, ethanol, glycerol, and poly-
ethylene glycol (PEG) 300 were purchased from Sigma-Aldrich
(Steinheim, Germany). Milli-Q water (SG Ultra Clear UV 2002, Evoqua
water Technologies LLC, Barsbüttel, Germany) was used for the DES
containing water as well as for the analytical work. Hydranal™ and
Hydranal™-solvent were bought from VWR International A/S
(Copenhagen, Denmark). All chemicals were analytical or Ph.Eur grade
and were used as received.
3.2. Methods
3.2.1. Preparation of deep eutectic solvents
The DESs listed in Table 1 were selected in order to cover a variety
of DES with different HBAs and HBDs. All the mixtures have previously
been described to be liquid at room temperature (Abbott et al., 2003;
Abbott et al., 2011; Benlebna et al., 2018; Dai et al., 2013; Dai et al.,
2015). The DESs were prepared by weighing the desired stoichiometric
amounts into a glass vial (with a maximum deviation between theoretic
and actual amount of 0.5 wt%). The glass vial was then sealed and the
physical mixtures were stirred by a magnetic stirring bar on a hotplate
at 50 °C, or at 80 °C (glucose containing DESs).
3.2.2. DES water content determination
The water content was determined using automated Karl Fischer
(KF) titration (870 KF Titrino, Mettler Toledo, Glostrup, Denmark) with
Hydranal™ in Hydranal™-solvent at room temperature. The Hydranal™-
solvent was dried by means of titration. When a steady baseline was
achieved, a given DES was added to Hydranal™-solvent by a syringe;
and the solution was thereafter stirred for 5min to ensure a homo-
geneous solution. The exact amount of DES was determined by
weighing the syringe before and after addition to the Hydranal™-sol-
vent. The titer was determined by sodium tartrate dihydrate (15.7 wt%
water) according to the European Pharmacopeia (2.5.12; method A).
3.2.3. Experimental solubility
The solubility of the APIs in water, DESs and conventional phar-
maceutical solvents was determined by addition of an excess amount of
solid API to approximately 2 g of DES. Agitation was applied by a
magnetic stirring bar in a sealed glass vial for 24 h at room temperature.
The solution was subsequently separated from the excess solid by
centrifugation at 15,000 rpm for 30min, the supernatant was hereafter
centrifuged for an additional 30min. If the excess solid separated to-
wards the top, the solid was removed and the sample centrifuged for an
additional 5min; this step was repeated until no solid material was
floating on top of the solution. Excess solid naproxen was removed from
glycerol by filtration (pore size 0.22 μm, Q-Max® NY, Frisnette,
Denmark), as separation of solid and liquid was not obtained after
centrifugation. The concentration of the API dissolved in the DESs was
quantified by UV-spectroscopy or high performance liquid chromato-
graphy (HPLC) with UV detection. A known amount of DES-API solu-
tion was diluted in a sufficient volume of ethanol and water (1:1) for
UV-spectroscopy and with mobile phase for HPLC analysis to ensure
that a solution without precipitates of API and/or DES components. The
solutions were visually inspected for precipitates.
3.2.4. High performance liquid chromatography (HPLC)
The chemical quantification was performed on Dionex HPLC system
(Dionex™, CA, USA). A known amount of DES-API solution was diluted
in mobile phase for HPLC analysis. All HPLC samples were injected
(2–50 μL) on a Kinetex® 5 μm EVO C18 100 LC column 100×4.6mm
(Phenomenex, Værløse, Denmark). The HPLC were equipped with an
ASI-100™ automated sample injector and P680 HPLC pump (Dionex™,
CA, United States) and a PDA-100 (Thermo Fisher Scientific, Waltham,
MA, USA) for UV-detection. The chromatograms were analysed using
Thermo Scientific Dionex Chromeleon 7 Chromatography Data System
Table 1
Deep eutectic solvents (DES) and molar composition.
DES Abbreviation Molar ratio
Choline chloride-urea CU 1:2
Choline chloride-glycerol CG 1:2
Choline chloride-lactic acid-water CLW 1:0.9:0.6
Betaine-glycerol-water BGW 1:2:1
Choline chloride-glucose-water CGluW 1:0.4:1
Lactic acid-glucose-water LGluW 1:0.2:1.2
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software (Thermo Fisher Scientific, Waltham, MA, USA).
Standard curves were constructed by serial dilution of stock solution
in mobile phase. All samples were within the concentration range of the
standard curve (R2 > 0.99) and above the limit of quantification. For
all methods (see Table 2) a constant flow rate of 1mL/min were ap-
plied.
3.2.5. UV-spectroscopy
A known amount of DES-API solution was diluted in a sufficient
volume of ethanol and water (1:1 v/v).The concentration of the API
dissolved in the DESs was quantified by UV-spectroscopy (UV-1800,
Shimadzu, Japan). All samples were within the concentration range of
the standard curve (R2 > 0.99) and above the limit of quantification.
The detection wavelength for ibuprofen, lidocaine, naproxen, para-
cetamol, and theophylline were 260, 253, 275, 260, and 272 nm re-
spectively.
3.2.6. Computational solubility predictions
The COSMO-RS method was used for computational predictions of
the relative solubility of the APIs in DESs. COSMO files with a TZVP
quantum chemical level were obtained from Turbomole version 7.3
(Ahlrichs et al., 1989). The computational solubility predictions were
performed by COSMOtherm (COSMOlogic GmbH & Co. KG, Le-
verkusen, Germany; Eckert and Klamt, 2002) with the TZVP_18.ctd
parameterisation. The solubility was predicted by the iterative method
both in water, ethanol, and in the DESs by selecting a solvent mixture
with the molar compositions equal to the DESs. All solvent - and API
molecules were treated as unionised and only present in the most stable
conformation. COSMO-RS is a fluid phase thermodynamic model, and
for that reason, computational predictions of absolute solubilities re-
quire information about the free energy of fusion for each component.
To avoid input of experimental values the fusion energies (ΔGfus) are
estimated by a group contribution method in the COSMOtherm soft-
ware. However, this estimation of the fusion energy compromises the
solubility predictions. Hence, in order to circumvent the challenges of
predicting the fusion energies, the solubility was predicted as a relative
solubility rather than an absolute solubility. Since experimental solu-
bilities for aprepitant and probucol in water could not be determined
because of their poor aqueous solubility, ethanol was used as a re-
ference for these two APIs.
4. Results
4.1. Water content of the deep eutectic solvents
The water content of the DESs was determined using Karl Fischer. It
was possible to analyse four out of six DESs; the remaining two DESs
systems contained glucose and could not be analysed with the current
KF solvents. The DES contained following percentage of water: 0.2% w/
w in CG, 0.1% w/w in CU, 6.1% w/w in CLW and 5.0% w/w for BGW.
These results are in agreement with the starting composition of the
DESs. While the majority of the DES had absorbed moisture during
handling, BGW and CLW had lost water during the preparation of the
DES. Thermogravimetric methods were also applied but the results
overestimated the water content due to evaporation of the DES com-
ponents.
4.2. Experimental solubility
The solubilities of the APIs in water, conventional pharmaceutical
solvents, and DESs are presented in Fig. 2, Table 3, and Fig. S1. The
APIs covered a broad range of solubilities, where some APIs showed a
narrow solubility span (e.g. paracetamol and theophylline) and other
APIs a broad solubility span (e.g. celecoxib and flufenamic acid) in the
studied solvents. The solubility of the APIs in the majority of DESs and
conventional pharmaceutical solvents were substantially higher com-
pared to the solubility in water. When comparing the solubilities of the
11 APIs in the three conventional solvents, PEG 300 and ethanol were
better solvents than glycerol (Fig. 2). With respect to the studied DESs,
the solvation capacity was generally in a similar range as the conven-
tional pharmaceutical solvents and very comparable to glycerol.
For four out of 11 APIs, the solubility was higher in a DES than any
of the conventional pharmaceutical solvents. Lidocaine had the highest
solubility in LGluW (469.4 mg/g), paracetamol in CLW (200.5mg/g),
theophylline in LGluW (63.5 mg/g), and aprepitant in LGluW (7.22mg/
g). The LGluW system contained the largest molar ratio of lactic acid of
the DES in the study. As lactic acid is liquid at room temperature the
solubility of lidocaine, theophylline, and aprepitant was measured in
lactic acid alone. Lidocaine was found to form a very viscous liquid
mixture in a 1:1 molar ratio with lactic acid at room temperature. The
solubility of theophylline and aprepitant was measured to be
Table 2
High performance liquid chromatography method details.
API Aqueous mobile phase Organic mobile phase Composition (v/v) Detection wavelength (nm) Retention time
Indomethacin Water+0.05% trifluoroacetic acid Acetonitrile+ 0.05% trifluoroacetic acid 50:50 264 3.7
Cinnarizine 5mM phosphate buffer, pH 10 Acetonitrile 30:70 220 5.1
Probucol Water Acetonitrile 90:10 200 6.2
Flufenamic acid 0.1% phosphoric acid Acetonitrile 45:55 200 8.3
Celecoxib Water Acetonitrile 60:40 254 2.4
Aprepitant 25mM ammonium acetate Acetonitrile 45:55 220 2.4
Fig. 2. Graphical representation of the experimental logarithmic solubility
(mole/mole) of the APIs in the DESs, water, and conventional solvents. The
colours green and red indicate high and low solubility, respectively. The solu-
bility of aprepitant and probucol was below the limit of quantification in water
and the missing data is indicated by a cross. The circles indicate API-DES
combinations that outperform conventional pharmaceutical solvents in a w/w
solubility. (For interpretation of the references to colour in this figure legend,
the reader is referred to the web version of this article.)
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116.4 ± 2.7 and 83.5 ± 22.8 mg/g in lactic acid, which is 1.8 and 12-
fold higher than in LGluW, respectively. Thus, none of these three APIs
were more soluble in LGluW than in lactic acid alone. On the other
hand, paracetamol had a solubility of 96.5 ± 5.5mg/g in lactic acid.
Thus, despite the limited data set, it was possible to find one API-DES
combination (paracetamol-CLW) for which the API solubility was
higher than in any single component solvent. High solubilities of
paracetamol were also obtained in CU, CG and BGW with a solubility of
122, 94.8, and 80.3mg/g, respectively. The solubility of paracetamol,
ibuprofen, and naproxen in CU, CG, and CLW has previously been re-
ported by (Lu et al., 2016) along with the solubility of other non-ster-
oidal anti-inflammatory APIs in various DES systems. The reported
solubilities of these nine API-DES combinations are consistent with the
solubilities obtained in this study (see Table S1). No signs of chemical
degradation could be observed based on the chemical analysis.
4.3. Computational solubility
The solubility of the APIs was predicted in the molar composition of
the DES as well as in glycerol, ethanol, PEG 300, and water. The pre-
dicted solubilities of the different APIs grouped similarly to the ex-
perimental data, as indicated by the similarity of Figs. 2 and 3 (the
numeric values can be found in Figs. S1 and S2). This is further sup-
ported by plotting (R2= 0.68; Fig. 4) the experimental solubility data
against the computationally predicted data. For solvents with a con-
siderable solubility difference it was possible to rank-order the solvents.
However, for solvents with a roughly similar solubility it was not pos-
sible to obtain a correct rank-order.
In order to improve the predictive capability of the COSMO model,
the relative solubilities were compared, which allows avoiding the
challenges associated with estimating the free energy of fusion for each
compound. The systematic shifts for some APIs (aprepitant, cinnarizine,
flufenamic acid, and probucol) that were observed in Fig. 4 were to a
great extent eliminated in Fig. 5, which indicate that this systemic shift
have been due to the estimation of free energy of fusion. The solubilities
of the APIs in DESs relative to water provide insights into the enabling
potential of the DESs for poorly water soluble APIs. For this reason,
combined with the availability and low costs, water was chosen as the
primary reference solvent. For probucol and aprepitant it was not
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Fig. 3. Graphical representation of the COSMO-RS predicted logarithmic solu-
bility (mole/mole) of the APIs in the DESs, water, and conventional solvents.
The colours green and red indicate high and low solubility, respectively.
Missing data is indicated by crosses. (For interpretation of the references to
colour in this figure legend, the reader is referred to the web version of this
article.)
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possible to experimentally determine the solubility in water and
ethanol was for that reason used as an alternative reference solvent. A
comparison of the experimental and predicted relative solubility of the
investigated APIs is presented in Fig. 5. It can be seen that the com-
putational solubility prediction improved significantly (R2= 0.83).
5. Discussion
5.1. Experimental solubility
The solubility results demonstrated the possibility to obtain high
solubilities of APIs in DES systems; however, the results also showed
that the solubility for most APIs was higher in the conventional
pharmaceutical solvents. Although conventional pharmaceutical sol-
vents generally have better solvation properties than DESs some of the
conventional pharmaceutical solvents also have clear limitations to
their use due to toxicity and/or religious non-acceptance such as
ethanol. The solubility of paracetamol was 1.3-, 2.0-, 2.1-, and 9.7-fold
higher in CLW (200mg/g) than in ethanol, glycerol, lactic acid, and
PEG 300, respectively. Of all investigated APIs and solvents, celecoxib
showed the largest increase in solubility relative to water, which was
4.91 log units (mole/mole) higher in CLW (18.3 ± 0.0mg/g) com-
pared to water (0.00148 ± 0.00007mg/g). These results demonstrate
that it is possible to obtain solubilities of APIs in DESs that exceed the
solubility in conventional pharmaceutical solvents.
The solubility of the APIs in DESs was for the majority of combi-
nations considerably higher than in water and to some degree com-
parable to the conventional pharmaceutical solvents. The hydrophilic
nature of the individual components in the selected DESs, may have
been a limiting factor for the solubility for some of the APIs. With po-
tentially 106 different DESs it may be possible to obtain higher solu-
bilities with other DESs; which are made by components with the ideal
polarity and functional groups to facilitate a higher solubility. It may
also be possible to optimising the molar composition of the DESs as
demonstrated by (Lu et al., 2016).
Based on this study, DESs present a potential alternative to con-
ventional pharmaceutical solvents for poorly soluble APIs. DESs pro-
vide the opportunity to access solvation properties of otherwise solid
components and to design solvents that are optimal for a specific API or
formulation. However, the numerous potential combinations of com-
ponents and molar ratios emphasise the need for computational
methods that can reduce the amount of experimental work required.
5.2. Computational solubility predictions
Experimental solubility measurements are time and labour con-
suming. Computational methods would therefore be highly valuable to
identify the most promising DESs for a given API. The computational
approach based on the COSMO-RS predictions of absolute solubilities
indicates the potential of this method for a rough selection of promising
DES-API combinations (Fig. 4). A better approach to avoid the
Fig. 4. A) Predicted vs. experimental solubility for all 11 APIs in water,
glycerol, ethanol, PEG 300 and the six different DESs ( CU, CG, BGW,
CGluW, LGluW, and CLW). The black solid line illustrates the ideal fit and
the grey dotted line represents the expected 0.95 confidence interval of the
computational predictions. Slope of best linear fit= 0.90, intercept= 0.053,
R2= 0.68. RMSE=1.044. B) Predicted vs. experimental solubility plotted ac-
cording to API. Aprepitant, celecoxib, cinnarizine, flufenamic acid,
ibuprofen, indomethacin, lidocaine, naproxen, paracetamol, probucol,
and theophylline.
Fig. 5. The experimental solubility and COSMO-RS predicted solubility in DES
relative to water (* or ethanol). The black solid line illustrates the ideal fit and
the grey dotted line represents the expected 0.95 confidence interval of the
computational predictions. Slope of best linear fit= 1.07, intercept=−0.18,
R2=0.82, RMSE=1.042. Aprepitant*, celecoxib, cinnarizine, flufe-
namic acid, ibuprofen, indomethacin, lidocaine, naproxen, para-
cetamol, probucol*, and theophylline.
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challenges of predicting the energy of fusion was to predict the relative
solubility (Fig. 5). The plot demonstrates that COSMO-RS is able to
guide the selection of API-DES combinations in order to potentially ease
the time-consuming experimental solubility screening associated with
identification of promising API-DES combinations. Furthermore, the
best linear fit slopes of 0.90 and 1.07 in Figs. 4 and 5, respectively,
demonstrated that the solvation of APIs in DESs roughly follow the
existing fluid phase thermodynamic theory that COSMO-RS is based on.
Computational prediction of the solubility of APIs in conventional
pharmaceutical solvents by COSMO-RS has previously been reported by
(Pozarska et al., 2013) where the predictions showed the same rank-
order for 5 out of 7 APIs between the COSMO-RS predicted and ex-
perimental rank-order for the majority of the 16 pure solvents such as:
Ethanol, PEG 400, dimethyl sulfoxide, benzyl alcohol, oleic acid, etc.
The results from this study further supports that COSMO-RS is a useful
tool to assess a solvent ranking for a given API, including also multi-
component solvents such as DESs. This may in future help to ease the
selection of the right solvent with the most pronounced solubilisation
increase. While the computational predictions can reduce the experi-
mental workload to select the best solvents among a set of given sol-
vents, the computational predictions cannot replace the experimental
measurements of the absolute solubilities in these solvents.
6. Conclusion
Overall, conventional pharmaceutical solvents performed generally
equivalent to or better than the investigated DESs in solvating the 11
APIs of this study. However, for four out of 11 APIs, the solubility was
higher in a DES than in any of the conventional pharmaceutical sol-
vents. When testing the solubility in the liquid components of the DESs,
we successfully identified one API-DES combination in which the API
solubility was higher than in any conventional pharmaceutical solvent
or single component of the DESs. The solubility of paracetamol was 1.3,
2.0-, 2.1-, and 9.7-fold higher in a DES containing choline chloride,
lactic acid and water (200mg/g), compared to ethanol, glycerol, lactic
acid, and PEG 300, respectively. The highest solubility difference be-
tween water and DES was measured for celecoxib where the solubility
was 4.91 log units (mole/mole) higher in DES (18.3 mg/g) compared to
water (0.00148mg/g). Hence, DESs are potential carriers for poorly
soluble APIs as they showed high relative solubilities of poorly soluble
APIs. Given the limited number of DES tested in this study compared to
the numerous potential DESs available, other DES compositions with
even higher solvation capacities could potentially exist. Nevertheless,
finding such a feasible DES-API combination can be very labour in-
tensive and predictive tools are therefore essential for a fast feasibility
assessment of DESs as alternatives to conventional pharmaceutical
solvents. The results from this study showed that the relative solvation
capacities could be rank-ordered (R2=0.82) ab initio using COSMO-RS
calculations. Hence, COSMO-RS may in the future be used to reduce the
experimental solvent screening for identification of the best DES for a
given API, particularly in expanded systematic studies with a large
number of DES combinations.
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